Loading
A phase 1/2 trial of Aminolevulinic acid (topical, for photodynamic therapy) in glioma & glioblastoma, run by Hemerion Therapeutics, active and no longer recruiting.
A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma is a phase 1/2 interventional study registered as NCT05736406 by Hemerion Therapeutics, with 12 participants enrolled, started 2024-02-20 and due to reach its primary completion in 2026-03-06. Interventions recorded: 5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 200 J/cm^2 and 5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 400 J/cm^2.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Aminolevulinic acid (topical, for photodynamic therapy), Thermal ablation and cryotherapy for cervical precancer, Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Aminolevulinic acid (topical, for photodynamic therapy) and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/